All News

Treatment-induced menopause can occur with severe symptoms, making personalized management and careful therapy selection essential.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

Research highlights the complex cognitive difficulties faced by breast cancer survivors, emphasizing the need for multifaceted treatment approaches, says Xiaotong Li, PhD, MS.

Discover key insights from the ERS Congress 2025, highlighting advancements in pulmonary fibrosis treatment and the promising role of nerandomilast.

The incidence of age-related macular degeneration could be linked to handgrip strength according to an analysis of the UK Biobank.

Recent studies highlight ustekinumab's effectiveness and safety in treating Crohn disease, especially for patients unresponsive to prior therapies.

Experts at SABCS 2025 said alcohol consumption raises breast cancer risk, emphasizing the need for public education and clinical intervention.

In case you missed it: the top 5 highlights from the Menopause Society's 2025 Annual Meeting.

If validated prospectively, the classifier could provide oncologists with clearer prognostic insight, enabling more personalized chemotherapy decisions, earlier intervention for high-risk patients, and potential adaptation across STS and other cancer types.

A small set of pre-apheresis biological factors can reliably predict whether patients with DLBCL will achieve the T cell collection efficiency needed for successful CAR T manufacturing

A review of 560 FDA-approved drugs found the FDAAA did not change overall time to first postmarket safety action, but some actions occurred earlier.

Common and rare genetic variants linked to idiopathic pulmonary fibrosis (IPF) and reveals substantial genetic overlap with severe COVID-19, highlighting shared biological pathways and potential therapeutic targets.

At SABCS 2025, Amrita Basu, PhD, underscores that effective AI use for breast cancer care depends on human oversight.

Research at the San Antonio Breast Cancer Conference highlights T-DXd's superior efficacy and safety in HER2+ metastatic breast cancer, especially among diverse populations.

Discover more about seasonal affective disorder in this interview with Craig Sawchuk, PhD, LP, clinical psychologist at Mayo Clinic.

Innovative deep proteomic profiling reveals promising results from a blood-based test for early breast cancer, showcasing high sensitivity and specificity, explains Justin Drake, PhD.

As value-based care mandates expand, a new survey highlights documentation burdens and burnout risks.

Democrats move to extend ACA subsidies as enrollment closes, leaving consumers uncertain about premiums, coverage, and alternative health options.

Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.

A low-protein diet is essential for managing chronic kidney disease (CKD), potentially slowing progression and improving health outcomes while tailoring to individual needs.

A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.

School reopenings after COVID-19 closures significantly improved children's mental health, reducing diagnoses of depression, anxiety, and ADHD.

New research highlights INCA033989's potential in treating mutCALR-driven essential thrombocythemia and myelofibrosis, achieving significant molecular responses.

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

While DTC pharmacy models offer convenience, they may create cost, access, and guidance barriers for the "working poor."

SABCS 2025 will spotlight new advances in breast cancer research while offering networking opportunities to foster connections among attendees.

Updated results highlight the promise of epcoritamab combined with chemotherapy for newly diagnosed DLBCL.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.